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DISCUSSION
Lupus cerebritis is an aggressive diagnostic entity that requires prompt and thorough 
evaluation, as it responds well to treatment. Diagnostic dilemmas are myriad in such cases, as 
the abundance of symptoms as well as multiorgan system involvement clouds the differential 
diagnosis. Neuropsychiatric symptoms of lupus cerebritis are not always present in patients 
who are newly diagnosed with SLE. Estimates are that between 28% and 40% of patients with a 
new diagnosis of SLE manifest neuropsychiatric symptoms. 
The numerous neuropsyhiatric symptoms in SLE are often characterized on central nervous 
system (CNS) and peripheral nervous system (PNS) involvement. CNS symptoms include aseptic 
meningitis, cerebrovascular disease, cognitive dysfunction, headache, demyelinating 
syndromes, movement disorders, seizure disorders and transverse myelopathy. PNS symptoms 
include autonomic neuropathy, peripheral neuropathy, and sensorineural hearing loss.
Mechanisms by which SLE provoke neuropsychiatric symptoms include autoantibody 
production, microangiopathy, production of proinflammatory cytokines, and atherosclerosis. 
The most common microscopic brain findings in the CNS are microvasculopathy. This case 
demonstrates some of the many neurological findings associated with lupus 
cerebritis provoked by untreated SLE. The inflammatory state triggers headache, and irritation 
of brain parenchyma ultimately provokes seizures. Cortical irritation breaks down the blood 
brain barrier and precipitates cognitive dysfunction, as cytokines infiltrate brain tissue.
Once the diagnosis is confirmed, treatment is effective and well tolerated. Symptomatic 
treatment is always warranted. As in our patient, antiseizure medications are often part of the 
treatment regimen. Steroids are the mainstay of SLE treatment, and coincidentally can also 
help with headache. As treatment progresses, encephalopathy and cognitive dysfunction 
improve with diminution of the inflammatory state. Most patients with SLE will eventually 
require chronic autoimmmune therapy, as our patient was placed on, and may be able to taper 
off symptomatic neurologic treatments, provided that they do not suffer permanent central 
nervous system damage.
HOSPITAL COURSE
The case we present is of a 38 year old African American female, who had no 
significant medical history other than a remote history of head trauma with 
two associated seizures that had occurred over fifteen years prior to her 
hospitalization. The patient presented to the hospital with acute 
encephalopathy and possible seizure like activity that occurred prior to 
arrival.
The patient had a complicated hospital course. Upon initial presentation 
patient was noted to be febrile and tachycardic, a lumbar puncture was 
performed and CSF studies noted a lymphocytic predominant pleocytosis and 
a negative meningoencephalitis panel. Patient was loaded and started on 
Keppra given the concern for seizure like activity prior to hospital arrival, had 
multiple EEGs that were negative for any epileptiform activity and had imaging 
of her Neuro-axis which was essentially unremarkable. She also underwent a 
CTA head/neck which was unremarkable and was unfortunately unable 
to tolerate a four vessel angiogram to assess for findings consistent with 
vasculitis. The patient was also found to have a pleural effusion and 
underwent thoracentesis, in which fluid studies were consistent with an 
exudative effusion, patient also underwent extensive laboratory testing which 
was essentially unremarkable other than the fact that serological testing 
for lupus came back positive, rheumatology was consulted, and the decision 
to start the patient on steroids in addition to mycophenolate mofetil was 
made for the diagnosis of SLE, only after the course of steroids and being on 
an immunosuppressant agent, did the patient begin to respond and follow 
commands allowing for a successful extubation.
PROGNOSIS
Patients presenting with acute central nervous system manifestations of SLE generally require 
treatment in an intensive care unit with neuroimaging capabilities. Treatment modalities 
generally vary in regards to the degree of severity of the acute attack, and a consulting 
Rheumatologist should be in cooperation. There is varied evidence on a logical therapeutic 
approach to the treatment of cerebral lupus due to the various pathogenesis. However, in 
general treatments consist of high dose IV corticosteroid regiments, antimalarials, cytotoxic 
agents such as cyclophosphamide, azathioprine, methotrexate or 
investigational pharmacological approaches such as Mycophenolate mofetil; which was used in 
our patient. Prognosis regarding CNS specific statistics are not available, however neurological 
complications generally worsen prognosis, in the setting of refractory seizures, encephalopathy, 
or paralysis from myelopathy or stroke. The overall outcome and quality of life for patients with 
CNS lupus manifestations can be enhanced with close follow up and coordination between 
the patient’s Neurologist, Rheumatologist, and Primary Care Physician.
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INTRODUCTION
Systemic lupus erythematous (SLE) is a chronic autoimmune condition that 
can affect any organ system, and may involve the nervous system; and can 
present with a number of different neurologic and psychiatric 
syndromes Heller. Central nervous system neuropsychiatric lupus refers to the 
various psychiatric and neurologic manifestations that develop secondary to 
involvement of the CNS in patients with SLE Heller. The term lupus cerebritis 
refers to the neuropsychiatric manifestations of lupus that appear to have an 
organic, rather than psychiatric basis, rather than a pathophysiologic 
mechanism Heller. For most phenotypic manifestations of neuropsychiatric SLE, 
no biomarkers or diagnostic tests are specific enough to attribute neurologic 
diagnosis to SLE, thus diagnosis of neuropsychiatric SLE nearly always 
requires rigorous exclusion of other causes Gelfand.
IMAGING
The patient underwent comprehensive multiorgan imaging evaluation given her constellation of 
symptoms. This included magnetic resonance imaging of the neuraxis. Brain MRI did not reveal 
evidence of ischemia, and contrast sequences were not revealing of underlying infection or mass 
lesion. Spinal MR imaging was unrevealing for mass lesions or inflammatory processes. She 
underwent serial electroncephalography (EEG) monitoring given that her initial presentation involved 
a witnessed seizure. Multiple EEGs were performed, demonstrating bihemispheric slowing without 
evidence of epileptiform discharges. These EEG findings are consistent with non-specific 
encephalopathy, which corresponded with the patient’s initial clinical exam. As the patient’s 
mentation slowly improved and she became alert and oriented, serial EEG monitoring was no 
longer indicated and thus further studies were not performed.
CT angiogram of the head was performed to evaluate for vasculitis given the concern for autoimmune 
disease. This study revealed patent vasculature throughout both cerebral hemispheres and in the 
posterior circulation. There was no evidence of vascular malformation, 
including aneurysms, fistulas, dissections or stenosis. Part of the patient’s routine evaluation entailed 
a trans thoracic echocardiogram (TTE), which incidentally revealed a large pericardial effusion. She 
underwent repeat TTE following intervention and treatment which confirmed resolution of 
the effusion.
Fig 1 – Post-contrast MRI imaging did not reveal meningeal irritation to suggest underlying infection.
Fig 2 – Fluid attenuation inversion recovery sequence of MRI images demonstrates that brain 
parenchyma is preserved, with no evidence of microvascular ischemia.
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